Molecular Mechanism of p73-Mediated Regulation of Hepatitis B Virus Core Promoter/Enhancer II: Implications for Hepatocarcinogenesis

Journal of Molecular Biology

Volumn 378, Issue 1, 2008, Pages 20-30

  Buhlmann, Sven ^a   Racek, Tomas ^a   Schwarz, Alexandra ^b   Schaefer, Stephan ^a   Pützer, Brigitte M ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

core promoter enhancer II; HBV; HCC; p73; replication

Indexed keywords

HEPATITIS B CORE ANTIGEN; PROTEIN P73;

ARTICLE; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEPATITIS B VIRUS; LIVER CARCINOGENESIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; VIRUS INHIBITION; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 41149087132     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.02.021     Document Type: Article

References (41)

1. Parkin D.M. International variation. Oncogene 23 (2004) 6329-6340
2. Chan H.L., and Sung J.J. Hepatocellular carcinoma and hepatitis B virus. Semin. Liver Dis. 26 (2006) 153-161
3. Cougot D., Neuveut C., and Buendia M.A. HBV induced carcinogenesis. J. Clin. Virol. 34 (2005) 75-78
4. Kremsdorf D., Soussan P., Paterlini-Brechot P., and Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 25 (2006) 3823-3833
5. Guo W.T., Bell K.D., and Ou J.H. Characterization of the hepatitis B virus EnhI enhancer and X promoter complex. J. Virol. 65 (1991) 6686-6692
6. Yee J.K. A liver-specific enhancer in the core promoter region of human hepatitis B virus. Science 246 (1989) 658-661
7. Gerlich W.H., and Kann M. Hepatitis B. In: Collier L., and Sussmann M. (Eds). Topley Wilson's Microbiology and Microbial Infections (2005), Edward Arnold Ltd., London, UK
8. Moolla N., Kew M., and Arbuthnot P. Regulatory elements of hepatitis B virus transcription. J. Viral Hepatitis 9 (2002) 323-331
9. Gunther S., Fischer L., Pult I., Sterneck M., and Will H. Naturally occurring variants of hepatitis B virus. Adv. Virus Res. 52 (1999) 25-137
10. Tong S. Mechanism of HBV genome variability and replication of HBV mutants. J. Clin. Virol. 34 (2005) 134-138
11. Lee H., Kim H.T., and Yun Y. Liver-specific enhancer II is the target for the p53-mediated inhibition of hepatitis B viral gene expression. J. Biol. Chem. 273 (1998) 19786-19791
12. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 (1997) 809-819
13. Stiewe T., and Putzer B.M. Role of p73 in malignancy: tumor suppressor or oncogene?. Cell Death Differ. 9 (2002) 237-245
14. Stiewe T., Theseling C.C., and Putzer B.M. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J. Biol. Chem. 277 (2002) 14177-14185
15. Zaika A.I., Slade N., Erster S.H., Sansome C., Joseph T.W., Pearl M., et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 196 (2002) 765-780
16. Stiewe T., Zimmermann S., Frilling A., Esche H., and Putzer B.M. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res. 62 (2002) 3598-3602
17. Petrenko O., Zaika A., and Moll U.M. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol. Cell. Biol. 23 (2003) 5540-5555
18. Stiewe T., and Putzer B.M. p73 in apoptosis. Apoptosis 6 (2001) 447-452
19. Muller M., Schilling T., Sayan A.E., Kairat A., Lorenz K., Schulze-Bergkamen H., et al. TAp73/DeltaNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ. 12 (2005) 1564-1577
20. Stiewe T., Tuve S., Peter M., Tannapfel A., Elmaagacli A.H., and Putzer B.M. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin. Cancer Res. 10 (2004) 626-633
21. Tannapfel A., Wasner M., Krause K., Geissler F., Katalinic A., Hauss J., et al. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J. Natl. Cancer Inst. 91 (1999) 1154-1158
22. Xu Z.H., Zhao M.J., and Li T.P. p73beta inhibits transcriptional activities of enhancer I and X promoter in hepatitis B virus more efficiently than p73alpha. World J. Gastroenterol. 8 (2002) 1094-1097
23. Glebe D., Berting A., Broehl S., Naumann H., Schuster R., Fiedler N., et al. Optimised conditions for the production of hepatitis B virus from cell culture. Intervirology 44 (2001) 370-378
24. Gunther S., Li B.C., Miska S., Kruger D.H., Meisel H., and Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J. Virol. 69 (1995) 5437-5444
25. Doitsh G., and Shaul Y. Enhancer I predominance in hepatitis B virus gene expression. Mol. Cell. Biol. 24 (2004) 1799-1808
26. Ori A., Zauberman A., Doitsh G., Paran N., Oren M., and Shaul Y. p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53. EMBO J. 17 (1998) 544-553
27. Racek T., Mise N., Li Z., Stoll A., and Putzer B.M. C-terminal p73 isoforms repress transcriptional activity of the human telomerase reverse transcriptase (hTERT) promoter. J. Biol. Chem. 280 (2005) 40402-40405
28. Koutsodontis G., Vasilaki E., Chou W.C., Papakosta P., and Kardassis D. Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. Biochem. J. 389 (2005) 443-455
29. Yu X., and Mertz J.E. Promoters for synthesis of the pre-C and pregenomic mRNAs of human hepatitis B virus are genetically distinct and differentially regulated. J. Virol. 70 (1996) 8719-8726
30. Zhang P., and McLachlan A. Differentiation-specific transcriptional regulation of the hepatitis B virus nucleocapsid gene in human hepatoma cell lines. Virology 202 (1994) 430-440
31. Li J., and Ou J.H. Differential regulation of hepatitis B virus gene expression by the Sp1 transcription factor. J. Virol. 75 (2001) 8400-8406
32. Uchida T., Takahashi K., Tatsuno K., Dhingra U., and Eliason J.F. Inhibition of hepatitis-B-virus core promoter by p53: implications for carcinogenesis in hepatocytes. Int. J. Cancer 67 (1996) 892-897
33. Kwon J.A., and Rho H.M. Transcriptional repression of the human p53 gene by hepatitis B viral core protein (HBc) in human liver cells. Biol. Chem. 384 (2003) 203-212
34. Wang X.W., Forrester K., Yeh H., Feitelson M.A., Gu J.R., and Harris C.C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl Acad. Sci. USA 91 (1994) 2230-2234
35. Teramoto T., Satonaka K., Kitazawa S., Fujimori T., Hayashi K., and Maeda S. p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res. 54 (1994) 231-235
36. Schuttler C.G., Fiedler N., Schmidt K., Repp R., Gerlich W.H., and Schaefer S. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J. Hepatol. 37 (2002) 855-862
37. Putzer B.M., Stiewe T., Crespo F., and Esche H. Improved safety through tamoxifen-regulated induction of cytotoxic genes delivered by Ad vectors for cancer gene therapy. Gene Ther. 7 (2000) 1317-1325
38. Stanelle J., Tu-Rapp H., and Putzer B.M. A novel mitochondrial protein DIP mediates E2F1-induced apoptosis independently of p53. Cell Death Differ. 12 (2005) 347-357
39. Stoll-Becker S., Repp R., Glebe D., Schaefer S., Kreuder J., Kann M., et al. Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients. J. Virol. 71 (1997) 5399-5407
40. Nelson J.D., Denisenko O., Sova P., and Bomsztyk K. Fast chromatin immunoprecipitation assay. Nucleic Acids Res. 34 (2006) e2
41. Shats I., Milyavsky M., Tang X., Stambolsky P., Erez N., Brosh R., et al. p53-Dependent down-regulation of telomerase is mediated by p21waf1. J. Biol. Chem. 279 (2004) 50976-50985